Obesity, is widely recognized as the largest and fastest growing public health problem in the developed and developing world.
This three day event will discuss aspects of obesity development and treatment in n informal academic setting
This year there are three main topics for discussion
- Predicting obesity for the development of diagnosis and management
- Gene-environment interactions in obesity
- Anti-Obesity Drug Discovery and Development
With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding obesity.
This event has CPD accreditation
Who Should Attend
Biotech and Pharma Industry: CEOs, Chief Scientists, Group Heads, Senior and Junior Scientists, Research Managers
Academic and Research Institutes: Group and Lab Heads, Postdoctoral Scientists and Research Students
Clinical specialists: Clinicians and dieticians specialising in obesity
The Deadline for abstract submissions for oral presentation is Feb 10th 2014
Abstracts for poster presentation only can be submitted up to two weeks before the event
This event has an open oral and poster session. Abstracts for this session can be submitted on any subject related to Obesity
You can download the instructions for authors at www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf
Day 1: Predicting obesity for the development of diagnosis and management
Discovery of predictive markers to assess individual risk of developing obesity will be discussed in an informal setting with plenty of opportunity for networking and debate.
- Morning Poster Session: Predicting obesity for the development of diagnosis and management
- Afternoon Poster Session: Open Poster Session
Day 2: Gene-environment interactions in obesity
It has become clear that there are large individual differences in the responsiveness to well-defined energy balance manipulations to control obesity. Overfeeding as well as negative energy balance protocols indicate that the response to standardized experimental treatments is strongly influenced by genetic background. However, testing gene-environment interaction is a relatively new field. This session will discuss identifying the genetic and environmental risk factors (lifestyle and diet) for obesity and the evidence for gene-environment interaction will be examined.Session Chair: Dr Clare Llewellyn
, Lecturer in Behavioural Obesity Research, University College London and King’s College London, UK
Day 3: Anti-Obesity Drug Discovery and Development
Obesity, is widely recognised as the largest and fastest growing public health problem in the developed and developing world. Although prevention through education and changes to the obesogenic environment are long-term goals, treatment is required for those who are already obese. Surprisingly, however, treatment options remain quite limited. The main treatment modalities for overweight and obese individuals remain dieting and physical exercise. However some patients find that diet and exercise is not a viable option; for these patients, anti-obesity drugs can be a better alternative than surgery. The pharmacological management of obesity is therefore an exciting option. New treatments are essentially on the horizon, and novel research strategies have very recently come to the fore. This session will discuss the development of therapeutic agents that may reduce body weight by decreasing the consumption or absorption of food, and/or by increasing energy expenditure.
Gene-environment interactions in the triangular relationship between obesity, depression and cardiovascular disease
Obesity and metabolic health status: predictive gene signatures
Dr Janice E. Drew, Senior Research Fellow, University of Aberdeen, UK
Antipsychotics induced obesity: Direct actions on the adipocytes
Professor Nira Ben-Jonathan, Professor of Cancer and Cell Biology, University of Cincinnati, United States
Thiol redox state as a novel pharmacologic target for obesity
Dr Amany Elshorbagy, Visting Postdoctoral Research Fellow, Lecturer in Medical Physiology, University of Oxford, UK Universityi of Alexandria, Egypt
Biomarkers of IntakeDifferent expression of certain adipokines in subcutaneous and visceral tissues between obese and non-obese subjects and their correlations with clinical parameters and periphera metabolic factors.
Professor Jack Winkler, London Metropolitan University, UK
Dr Chantacha Sitticharoon
, Department of Physilogy, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Obesity, leptin and respiratory control
Dr Mirian Bassi, Post-Doctoral,School of Dentistry, São Paulo State University (UNESP), Araraquara, Sao Paulo-Brazil
Eating, Epigenetics and Ageing Well: Nature or Nurture: Findings from the Belfast Elderly Longitudinal Free Living Ageing STudy (BELFAST).
Dr Irene Maeve Rea, Senior Lecturer and Consultant Physician Geriatric Medicine, Queens University Belfast and Belfast Health and Social Care Trust, Northern Ireland
Genetic and Environmental Determinants of Comorbid Obesity in Major Psychiatric Disorders
Dr Margarita Rivera, Lecturer in Psychiatric Genetics, Institute of Psychiatry, King’s College London, UK
Galanin-like peptide (GALP) have anti-obesity effect via the activation of hepatic lipid metabolism
Dr Satoshi Hirako, Post-doctoral fellow, Dept of Anatomy, Showa University School of Medicine, Tokyo, Japan
Additional Confirmed Speakers Include
- Professor Gertjan Van Dijk, Center for Behavior and Neurosciences, University of Groningen, The Netherlands
- Dr L. Joseph Su, National Institutes of Health, National Cancer Institute, USA
- Dr Shahrad Taheri ,Senior Lecturer in Endocrinology, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, UK